The MYC Family: MYC, MYCN and MYCL

One Function, Three Genes

All three MYC proteins dimerise with the partner protein MAX and bind DNA at E-box sequences. Rather than switching a discrete set of genes on and off, they broadly increase transcription of already-active genes, a role sometimes described as transcriptional amplification.

The genes are expressed in different tissues and developmental windows: MYC is widespread, MYCN is prominent in neural and neuroendocrine precursors, and MYCL in lung and haematopoietic lineages.

MYC

MYC is deregulated in most cancers, through translocation (as in Burkitt lymphoma, where MYC is placed next to an immunoglobulin enhancer), amplification, enhancer hijacking, or increased upstream signalling from pathways such as Wnt and RTK-RAS.

Because MYC output depends on protein level and stability, tumours often raise MYC without mutating the coding sequence.

MYCN and MYCL

MYCN amplification defines a high-risk subset of neuroblastoma and is used for risk stratification and treatment intensity. It also occurs in medulloblastoma, retinoblastoma and treatment-emergent neuroendocrine prostate cancer.

MYCL amplification is characteristic of small cell lung cancer, alongside MYC and MYCN amplification in other cases, defining molecular subsets of that disease.

Why MYC Is Hard to Drug

MYC is a nuclear transcription factor with no enzymatic pocket and a large, disordered structure, so direct small-molecule inhibitors have been elusive. Its short half-life and broad essential functions also raise toxicity concerns.

Indirect strategies include BET bromodomain inhibitors that reduce MYC transcription, Aurora A inhibitors that destabilise N-MYC, disrupting the MYC-MAX interaction, and exploiting synthetic-lethal dependencies of MYC-driven cells. Most remain investigational.

Interpretation Notes

A MYC-family amplification report should specify which gene; MYCN in neuroblastoma has established prognostic and treatment implications that do not transfer to MYC or MYCL findings elsewhere.

MYC protein overexpression by immunohistochemistry and MYC rearrangement by FISH answer different questions, and both are used in lymphoma classification.

Key Takeaways

• ·MYC, MYCN and MYCL dimerise with MAX and broadly amplify active transcription.
• ·MYC is deregulated in most cancers, usually by raising protein level not by coding mutation.
• ·MYCN amplification stratifies neuroblastoma risk; MYCL amplification marks small cell lung cancer.
• ·Direct MYC inhibition is hard; BET, Aurora A and synthetic-lethal approaches are investigational.